Phác đồ giảm mỡ
Bộ nghiên cứu được khảo sát về kích hoạt đường dẫn oxy hóa mỡ và duy trì các chỉ dấu khối nạc ở đối tượng nghiên cứu.
What's in the stack
3 precision-matched compounds · 6 vials total for the 8-week cycle.
2× hộp 10 lọ2× Retatrutide
10mg / lọ · Bột đông khô
Peptide nghiên cứu đồng vận ba thụ thể GLP-1 / GIP / glucagon
2× hộp 10 lọ2× MOTS-c
10mg / lọ · Bột đông khô
Peptide chuyển hóa nguồn gốc ty thể
2× hộp 10 lọ2× L-Carnitine
10ml × 600mg/ml · Sterile solution
Phân tử vận chuyển axit béo ty thể
About the Phác đồ giảm mỡ
The Fat Loss Protocol pairs three compounds studied across distinct metabolic pathways: a tri-agonist incretin-receptor peptide (Retatrutide), a mitochondrially-derived metabolic peptide (MOTS-c), and a foundational fatty-acid transporter (L-Carnitine). The combination is designed for research applications investigating multi-pathway metabolic regulation rather than single-target intervention.
Each compound in the kit is HPLC-verified to ≥99% purity and shipped from Australian stock. The 8-week structure mirrors common research-cycle lengths used in published incretin-pathway and mitochondrial-function literature, with sufficient vial supply to support standard protocol designs without re-ordering mid-study.
Australian researchers studying peptides for fat oxidation, body composition, or metabolic flexibility have historically had to source these compounds from three separate suppliers. The protocol consolidates the supply chain into a single Australian-shipped kit, with batch-level certificates of analysis available for all three components.
Why these three compounds together
Retatrutide is studied as a tri-agonist of the GLP-1, GIP, and glucagon receptors — the same receptor family targeted by approved incretin-pathway medicines, but with the additional glucagon-receptor activity that distinguishes it pharmacologically. Research interest in Retatrutide has been driven by its multi-receptor profile, which is hypothesised to produce metabolic effects beyond single-receptor or dual-receptor compounds.
MOTS-c is one of the few characterised mitochondrially-encoded peptides — it is encoded within the mitochondrial 12S ribosomal RNA gene rather than the nucleus. Research on MOTS-c covers AMPK pathway activation, glucose homeostasis, and fatty-acid oxidation models. It is studied as a putative regulator of mitochondrial metabolic flexibility.
L-Carnitine is the cellular cofactor that transports long-chain fatty acids across the inner mitochondrial membrane for β-oxidation. Without sufficient carnitine, fatty acids cannot enter the mitochondrial matrix where β-oxidation occurs. Carnitine research has covered models of mitochondrial fatty-acid metabolism, exercise physiology, and metabolic flexibility — making it a foundational support compound for any research protocol investigating fat-oxidation pathways.
Cycle structure
The 8-week research-cycle window aligns with common protocol designs in incretin-pathway and mitochondrial-metabolism literature. Researchers typically use a three-phase structure: weeks 1-2 establish baseline measurements and titrate doses, weeks 3-6 cover the peak intervention window, and weeks 7-8 cover a taper and post-intervention measurement period.
Vial quantities in the kit are sized for the 8-week cycle at standard research-protocol dose ranges. Researchers should consult primary literature for protocol-specific dosing — the kit is supplied as research materials, not as a fixed clinical regimen.
Why these compounds together
Retatrutide kích hoạt tín hiệu chuyển hóa đa thụ thể, MOTS-c hỗ trợ oxy hóa mỡ tại ty thể, và L-Carnitine hỗ trợ vận chuyển axit béo vào ty thể. Nghiên cứu gợi ý tổ hợp này liên quan đến cải thiện các chỉ dấu thành phần cơ thể.
Nhà nghiên cứu tập trung vào kết cục thành phần cơ thể.
Research cycle structure
Phác đồ giảm mỡ — frequently asked questions
What is the Fat Loss Protocol?
The Fat Loss Protocol is an 8-week research-peptide kit containing Retatrutide (a GLP-1 / GIP / glucagon tri-agonist), MOTS-c (a mitochondrially-derived metabolic peptide), and L-Carnitine. All three compounds are studied in models of metabolic regulation, fatty-acid oxidation, and body composition. The kit is supplied for laboratory research use only.
What peptides are used for fat loss research?
The most extensively studied research peptides in fat oxidation and metabolic pathway literature include the incretin-receptor family (Retatrutide, tirzepatide, semaglutide), mitochondrial peptides (MOTS-c), and HGH fragments (AOD 9604). Foundational cofactors like L-Carnitine support the fatty-acid oxidation pathway. Quantum Labs' Fat Loss Protocol pairs three of these in a single research-grade kit.
Is the Fat Loss Protocol legal in Australia?
Retatrutide is not an approved therapeutic in Australia; MOTS-c is restricted for compounded human therapeutic supply; L-Carnitine is available for research and supplementary use. All three compounds in the kit are supplied without therapeutic representation, for laboratory research use only. Quantum Labs supplies this stack for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing or expected personal outcomes should be directed to a qualified medical practitioner.
How does the Fat Loss Protocol compare with Mounjaro or Wegovy?
Mounjaro (tirzepatide) and Wegovy (semaglutide) are approved prescription medicines dispensed through pharmacies on valid prescription. Retatrutide is a separate research peptide with additional glucagon-receptor activity — it is not an approved therapeutic and is not a substitute for prescription medicine. The Fat Loss Protocol is a research kit, not a treatment.
What does the Fat Loss Protocol kit contain?
The kit contains 2× Retatrutide vials, 2× MOTS-c vials, and 2× L-Carnitine vials — sized for the 8-week research cycle. All compounds are lyophilised, sealed, HPLC-verified ≥99% purity, and ship together from Australian stock with batch identifiers.
Is PCT needed for the Fat Loss Protocol?
Post-cycle therapy is generally associated with research protocols that involve hypothalamic-pituitary-axis suppression. The Fat Loss Protocol targets metabolic pathways (incretin-receptor, AMPK, fatty-acid oxidation) rather than the HPG axis, so structured PCT is not part of the standard protocol design.
Chỉ dùng cho nghiên cứu. Hợp chất này được bán nghiêm ngặt cho nghiên cứu in-vitro và mục đích phòng thí nghiệm, không dùng cho người hay mục đích điều trị. Khi mua, bạn xác nhận mình là nhà nghiên cứu đủ điều kiện và đồng ý với tuyên bố miễn trừ đầy đủ.
Ready to start this protocol?
All 6 vials sized for the 8-week cycle, plus the protocol guide PDF. Shipped worldwide.
Not sure? Take the 60-second quiz